Author(s): Harit Kasana, Harish Chander, Ashwani Mathur

Email(s): ashwani.mathur@mail.jiit.ac.in

DOI: 10.52711/0974-360X.2024.00378   

Address: Harit Kasana1,2, Harish Chander1, Ashwani Mathur2
1National Institute of Biologicals (Ministry of Health and Family Welfare, Government of India) A-32, Sector - 62, Noida - 201309, India.
2Department of Biotechnology, Jaypee Institute of Information Technology, Noida, A-10, Sector - 62, Noida, 201309, Uttar Pradesh, India.
*Corresponding Author

Published In:   Volume - 17,      Issue - 5,     Year - 2024


ABSTRACT:
A biosimilar is a copy of an approved original biologic drug. Call for biosimilars is triggered by the expiration of the data protection on the original biologic medicine. A similar biologic biopharmaceutical product has been approved by the European Medicines Agency (EMA) because of its similarity in quality, safety, and efficacy to an innovator biologic product. Many nations, including Canada, Japan, the United States, India, and Korea, have released their own standards for evaluating follow-on biologics, based on WHO and EMA guidelines. When it comes to licensing biosimilar products/entities, this page discusses widely accepted criteria, with the goal of guaranteeing quality, safety and efficacy after full licensing dossier submission and license approval. Clinical and non-clinical data obtained with a previously licensed similar biologic medicinal product will be used in part to evaluate the degree of similarity between biosimilar and innovator biologic products for the licensing process. National regulatory frameworks can be built on these guidelines to license the products in question. It is the purpose of this article to discuss the numerous regulatory requirements for biosimilar clearance, including the WHO and several areas, such as India and the EU, as well as the US.


Cite this article:
Harit Kasana, Harish Chander, Ashwani Mathur. A Systematic Review of Regulatory requirements of Biosimilar Products: WHO, India, European Union and USFDA. Research Journal of Pharmacy and Technology. 2024; 17(5):2413-0. doi: 10.52711/0974-360X.2024.00378

Cite(Electronic):
Harit Kasana, Harish Chander, Ashwani Mathur. A Systematic Review of Regulatory requirements of Biosimilar Products: WHO, India, European Union and USFDA. Research Journal of Pharmacy and Technology. 2024; 17(5):2413-0. doi: 10.52711/0974-360X.2024.00378   Available on: https://rjptonline.org/AbstractView.aspx?PID=2024-17-5-74


REFERENCES:
1.    Weise M, Bielsky MC, De Smet K, Ehmann F, Ekman N, Giezen TJ, Gravanis I, Heim HK, Heinonen E, Ho K, Moreau A. Biosimilars: what clinicians should know. Blood, The Journal of the American Society of Hematology. 2012 Dec 20;120(26):5111-7.
2.    Kumar R, Singh J. Biosimilar drugs: current status. IntJ Appl Basic Med. 2014 Jul; 4(2): 63.
3.    Wang J, Chow SC. On the regulatory approval pathway of biosimilar products. Pharmaceuticals. 2012 Mar 30;5(4):353-68.
4.    Sekhon BS, Saluja V. Biosimilars: an overview. Biosimilars. 2011 Mar 15;1:1-1.
5.    Weise M, Bielsky MC, De Smet K, Ehmann F, Ekman N, Narayanan G, Heim HK, Heinonen E, Ho K, Thorpe R, Vleminckx C. Biosimilars—why terminology matters. NatBiotechnol. 2011 Aug;29(8):690-3.
6.    Genazzani AA, Biggio G, Caputi AP, Del Tacca M, Drago F, Fantozzi R, Canonico PL. Biosimilar drugs. BioDrugs. 2007 Nov; 21(6): 351-6.
7.    Chauhan MK, Malik S. Regulatory guidelines for the approval of biosimilars in India. Europe, Brazil, and China: A comprehensive overview. http://innovareacademics. in/journals/index. php/ijpps/article/view/11753. 2016.
8.    Gray E, Mulloy B. Biosimilar low molecular weight heparin products. J ThrombHaemost. 2009 Jul; 7(7): 1218-21.
9.    Calvo B, Zuñiga L. The US approach to biosimilars. BioDrugs. 2012 Dec; 26(6): 357-61.
10.    Kumar R, Malgarini RB, Pimpinella G, Pani L, Pecorelli S, Memo M. Biosimilars: regulatory status and implications across the world. J Pharmacovigil. 2015 Sep 21..
11.    Jelkmann W. Biosimilar epoetins and other “follow‐on” biologics: Update on the European experiences. Am JHematol. 2010 Oct;85(10):771-80.
12.    McCamish M, Woollett G. Worldwide Experience with Biosimilar development. InMAbs. 2011 Mar 1; 3(2); 209-217. Taylor & Francis.
13.    Schellekens H. Biosimilar epoetins: how similar are they. Eur J Hosp Pharm. 2004; 3: 43-7. (2016). Retrieved 8 September 2021, from https://www.fdanews.com/ext/resources/files/2016/03/03-28-16-CDSCOBiosimilarGuidelines.pdf?1459187548
14.    Mellstedt H, Niederwieser D, Ludwig H. The challenge of biosimilars. Ann Oncol. 2008 Mar 1; 19(3): 411-9.
15.    Garcia R, Araujo DV. The regulation of biosimilars in Latin America. Current Rheumatol. Rep. 2016 Mar; 18(3):1-8..
16.    Wadhwa M, Thorpe R. The challenges of immunogenicity in developing biosimilar products. Idrugs: the Investigational Drugs Journal. 2009 Jul 1; 12(7): 440-4.
17.    Suh SK, Park Y. Regulatory guideline for biosimilar products in Korea. Biologicals. 2011 Sep 1; 39(5): 336-8.
18.    McCamish M, Pakulski J, Sattler C, Woollett G. Toward interchangeable biologics. Clin Pharmacol Therap. 2015 Mar; 97(3): 215-7.
19.    Halimi V, Daci A, AncevskaNetkovska K, Suturkova L, Babar ZU, Grozdanova A. Clinical and regulatory concerns of biosimilars: a review of literature. Int. J. Environ. Res. Public Health. 2020 Aug; 17(16): 5800.
20.    Rao SK. Pricing biologics: issues, strategic priorities and a conceptual model. Journal of Commercial Biotechnology. 2011 Feb; 17(1): 7-23.
21.    S. Janani, K. Manikandan, R. Kamaraj. Overview of Biosimilars. Research J. Pharm. and Tech. 2018; 11(11): 5152-5158. doi: 10.5958/0974-360X.2018.00941.1
22.    Elena VyacheslavnaLitvinova, Olga Viktorovna Posilkina, NataliiaFedorovnaMaslova. Formation of patent strategy at all stages of biosimilar development and Implementation. Research J. Pharm. and Tech. 2018; 11(7): 3081-3086. doi: 10.5958/0974-360X.2018.00566.8
23.    Ammar Almaaytah. A Review of the Non-clinical and Clinical Requirements for the performance of a comparability exercise for Bevacizumab biosimilars. Research Journal of Pharmacy and Technology. 2023; 16(7): 3499-6. doi: 10.52711/0974-360X.2023.00578
24.    Saha D, Jana M, Mandal S. Target Discovery and Validation: Advances in Molecular Pharmacology. Asian Journal of Pharmaceutical Analysis. 2011; 1(2): 27-8.
25.    Rawat S, Gupta A. Regulatory requirements for drug development and approval in united states: a review. Asian Journal of Pharmaceutical Research. 2011; 1(1): 1-6
26.    Abhimanyu T, Sushmita K, Shruti K, Amit K, Epshita G. Assessment of Prevailing Insurance Policies and Regulations in Context of Clinical Research Industry. Asian Journal of Pharmaceutical Research. 2015; 5(2): 114-7
27.    Kalpana Kamnoore, M P Venkatesh, Balamuralidhara V, T M Pramod Kumar. Regulatory requirements for conducting Clinical Trials in India. Research J. Pharm. and Tech. 2020; 13(3): 1517-1522. doi: 10.5958/0974-360X.2020.00276.0
28.    Lokesh. C, Sonia. K, Raju Kamaraj. Regulatory Requirements for Biological product approval process in India. Research J. Pharm. and Tech. 2020; 13(2): 1050-1054. doi: 10.5958/0974-360X.2020.00193.6
29.    Thaikadan Soorya Sukumaran, M. P. Venkatesh. Regulatory requirements for Post approval changes in Japan, Canada and Malaysia. Research J. Pharm. and Tech. 2020; 13(6): 2585-2590. doi: 10.5958/0974-360X.2020.00460.6
30.    B. Jayalakshmi, R. Seetharaman, R. Kamaraj. Registration and Regulatory Requirements of Generic Drugs Marketing Authorization in “BRICS” Countries. Research J. Pharm. and Tech. 2019; 12(3): 1403-1408. doi: 10.5958/0974-360X.2019.00234.8
31.    Subhash Chand, Anu Sharma, Jai Prakash Prasad, Girish Sharma. Synergistic Combinatorial effect of L-asparaginase and Trastuzumab against HER2+ breast cancer cells. Research Journal of Pharmacy and Technology. 2022; 15(12):5819-4. doi: 10.52711/0974-360X.2022.00982
32.    Vishal Vennu, Prem Saini. The knowledge and views of Indian researchers concerning India’s current drugs and clinical trial regulations. Research J. Pharm. and Tech. 2020; 13(9):4179-4184. doi: 10.5958/0974-360X.2020.00738.6

Recomonded Articles:

Research Journal of Pharmacy and Technology (RJPT) is an international, peer-reviewed, multidisciplinary journal.... Read more >>>

RNI: CHHENG00387/33/1/2008-TC                     
DOI: 10.5958/0974-360X 

1.3
2021CiteScore
 
56th percentile
Powered by  Scopus


SCImago Journal & Country Rank


Recent Articles




Tags


Not Available